Skip to content

A Clinical Study on the Improvement of Cardiopulmonary Function in Patients with Diffuse Coronary Artery Lesions After Percutaneous Coronary Intervention (PCI) by Blood-Activating and Toxin-Resolving Formula.

A Clinical Study on the Improvement of Cardiopulmonary Function in Patients with Coronary Artery Diffuse Lesions After Interventional Surgery by Huoxue Jiedu Formula

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000145
Enrollment
Unknown
Registered
2026-01-24
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart cardiovascular disease

Interventions

Control group:Huoxue Jiedu Formula placebo + Western medicine basic treatment, one packet each time, bid.
Experimental group:Blood-activating and detoxifying formula + Western medicine basic treatment, 1 bag each time, twice daily.

Sponsors

China Academy of Traditional Chinese Medicine, Xiyuan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects must meet all the following criteria to be eligible for inclusion in this trial: (1) Coronary angiography or CTA demonstrating diffuse (length > 20 mm) lesions; (2) Diagnosis of stable angina pectoris in coronary artery disease; (3) NYHA functional class I–III; (4) At least one coronary stent implanted within 2 years post-PCI; (5) Age 18 years = age = 75 years; (6) Diagnosis of TCM stasis-toxin syndrome; (7) Informed consent obtained from the subject.

Exclusion criteria

Exclusion criteria: Subjects meeting any of the following criteria will be excluded from this trial: (1) Severe renal impairment: serum creatinine >2.5 mg/dl (>220 µmol/l) in males or >2.0 mg/dl (>175 µmol/l); (2) Severe hepatic disease or ALT and AST levels both exceeding three times the upper limit of normal; (3) Controlled systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg; (4) Diabetes mellitus with random blood glucose =13.7 mmol/l or glycated haemoglobin =9.5%; (5) Pregnant women, women planning pregnancy, or breastfeeding women; (6) Patients with severe acute or chronic cerebrovascular disease; (7) Patients with malignant tumours; (8) Patients with severe haematopoietic system disorders; (9) Patients with severe psychiatric disorders; (10) Individuals with known hypersensitivity to any component of the study drug; (11) Participants who have enrolled in or are currently enrolled in another clinical trial within the preceding three months.

Design outcomes

Primary

MeasureTime frame
Cardiopulmonary Exercise Test: Peak Metabolic Equivalent, Peak Oxygen Uptake per Kilogram;

Secondary

MeasureTime frame
Cardiopulmonary exercise test: Oxygen threshold metabolic equivalents, Anaerobic threshold oxygen uptake per kilogram, Exercise duration, Power, Oxygen uptake, Heart rate, Oxygen pulse, Minute ventilation;Quality of life;Traditional Chinese Medicine Syndrome Scoring;Endpoint events and bleeding events;

Countries

China

Contacts

Public ContactWang Peili

Xiyuan Hospital, China Academy of Chinese Medical Sciences

659224730@qq.com18561845316

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026